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Abstract
Cancer patients undergoing treatment with systemic cancer chemotherapy drugs often have abnormal growth factor
and cytokine profiles. Thus, serum levels of interleukin-8 (IL-8) are elevated in patients with malignant melanoma. In
addition to IL-8, aggressive melanoma cells secrete, through its transcriptional regulator hypoxia-inducible factor 1
(HIF-1), vascular endothelial growth factor (VEGF), which promotes angiogenesis andmetastasis of human cancerous
cells. Whether these responses are related to adenosine, a ubiquitous mediator expressed at high concentrations in
cancer and implicated in numerous inflammatory processes, is not known and is the focus of this study. We have
examined whether the DNA-damaging agents etoposide (VP-16) and doxorubicin can affect IL-8, VEGF, and HIF-1
expressions in humanmelanoma cancer cells. In particular, we have investigated whether these responses are related
to the modulation of the adenosine receptor subtypes, namely, A1, A2A, A2B, and A3. We have demonstrated that A2B
receptor blockade can impair IL-8 production, whereas blocking A3 receptors, it is possible to further decrease VEGF
secretion in melanoma cells treated with VP-16 and doxorubicin. This understanding may present the possibility of
using adenosine antagonists to reduce chemotherapy-induced inflammatory cytokine production and to improve the
ability of chemotherapeutic drugs to block angiogenesis. Consequently, we conclude that adenosine receptor modu-
lation may be useful for refining the use of chemotherapeutic drugs to treat human cancer more effectively.
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Introduction
The incidence and mortality of cutaneous melanoma are still on the
rise [1]. Overall, melanoma accounts for 1% to 3% of all malignant
tumors and is increasing in incidence by 6% to 7% each year. The
prognosis of metastatic melanoma remains poor. Once the metastatic
phase develops, it is almost always fatal [2]. Different therapeutic
approaches for metastatic melanoma have been evaluated, including
chemotherapy and biologic therapies, both as single treatments and
in combination [3]. To date, however, none have had a significant im-
pact on survival. Systemic chemotherapy is still considered the mainstay
of treatment of stage IV melanoma and is used largely with palliative
intent [3]. Numerous chemotherapeutic agents have shown some ac-
tivity in the treatment of malignant melanoma with dacarbazine
(DTIC) being themost widely used [4]. DTIC is a nonclassical alkylating
agent, generally considered the most active agent for treating malignant
melanoma [4]. However, response rates for single-agent DTIC are dis-
appointing [5,6].
A major obstacle to a successful treatment of metastatic melanoma is
its notorious resistance to chemotherapy [7]. Chemoresistance is widely
explored in cancer research, and many mechanisms have been described
by which a tumor can evade cell killing in a variety of malignancies [8].
However, the mechanisms of chemoresistance of malignant melanoma
are not established.
The aggressive nature of human melanomas is related to several ab-
normalities in growth factors, cytokines, and their receptor expression.
For example, metastatic melanoma cells constitutively secrete the cyto-
kine interleukin-8 (IL-8), whereas nonmetastatic cells produce low to
negligible levels of IL-8 [9–11]. In fact, IL-8, originally discovered as
a chemotactic factor for leukocytes, may play an important role in the
progression of humanmelanomas [10]. Serum levels of IL-8 are elevated
in patients with malignant melanoma [12], and several studies have
demonstrated that the expression levels of this interleukin correlate with
disease progression in humanmelanomas in vivo [12–16]. In addition to
IL-8, aggressive melanoma cells secrete vascular endothelial growth
factor (VEGF), which promotes angiogenesis and metastasis of human
cancerous cells [17]. Cytotoxic therapy, including radiotherapy, and
other stress conditions such as hypoxia are known to induce IL-8 and
VEGF release by tumor cells [18,19]. In particular, hypoxic induction of
VEGF ismediated by the transcription factor hypoxia-inducible factor 1
(HIF-1), which plays a key role in regulating the adaptation of tumors to
hypoxia [20]. HIF-1 is a heterodimer composed of an inducibly ex-
pressedHIF-1α subunit and a constitutively expressedHIF-1β subunit.
A growing body of evidence indicates that HIF-1 contributes to tumor
progression andmetastasis [20,21]. HIF-1 is a potent activator of angio-
genesis and invasion through its up-regulation of target genes critical for
these functions [20]. Therefore, becauseHIF-1α expression and activity
seem central to tumor growth and progression, HIF-1 inhibition be-
comes an appropriate anticancer target [20].
Adenosine is a ubiquitous mediator implicated in numerous in-
flammatory processes [22]. Accumulating evidence suggests that
adenosine-mediated pathways are involved in cutaneous inflammation
and epithelial cell stress responses. Most adenosine effects are mediated
by its interaction with four seven-transmembrane G protein–coupled
receptor, namely, A1, A2A, A2B, and A3 [23]. Recently, it has been
reported that epithelial cells release adenosine in response to various
stimuli, including adenosine receptor agonists [24]. Moreover, we have
demonstrated that, in addition to producing adenosine, melanoma cell
lines also express functional adenosine receptors [25,26]. In particular,
activation of A2B receptor leads to the production and release of cal-
cium, VEGF, and IL-8 [27–29], whereas A3 receptor leads to the pro-
duction and release of calcium, VEGF, and angiopoietin-2 [30–35].
Recently, we have demonstrated that A3 receptor induces a prosurvival
signal in tumor cells [36]. Furthermore, A3 receptor stimulation in-
creases the levels of HIF-1α in hypoxic tumor cells [28,31,33].
Here, we investigate whether two chemotherapeutic drugs, etoposide
(VP-16) and doxorubicin, modulate IL-8 and VEGF production in
human melanoma A375 cells. In particular, because adenosine is able
to modulate HIF-1, VEGF, and IL-8 in cancer cells, we analyze the
influence of the adenosinergic signaling on the chemotherapeutic drug
effects in human melanoma cells.
We found, for the first time, that A2B receptor blockade can modu-
late IL-8 production, whereas blocking A3 receptors, it is possible to
further decrease VEGF reduction due to VP-16 and doxorubicin in
melanoma cells. We thus conclude that adenosine receptor modulation
may be useful with chemotherapeutic drugs for the treatment of malig-
nant melanoma.
Materials and Methods
Cell Lines, Reagents, and Antibodies
A375 human melanoma cells were obtained from American Tissue
Culture Collection, LGC Standards s.r.l., Milano, Italy. Tissue cul-
ture media and growth supplements were obtained from Cambrex
(Bergamo, Italy). Anti–adenosine A2B and anti–adenosine A3 receptor
polyclonal antibodies (pAbs) were fromAlphaDiagnostic (DBA,Milano,
Italy). Human anti–HIF-1α and human anti–HIF-1βmonoclonal anti-
bodies (mAbs) were obtained from Transduction Laboratories (Milano,
Italy). U0126 (inhibitor of MEK-1 and MEK-2), SB 202190 (inhibitor
of p38mitogen-activated protein kinase (MAPK)), human anti-ACTIVE
MAPK and human anti–extracellular signal–regulated kinase 1/2 (ERK
1/2) pAbs were from Promega (Milano, Italy). SH-5 (inhibitor of Akt)
was from Vinci-Biochem (Florence, Italy). [3H]-Thymidine was from
Perkin-Elmer Life and Analytical Sciences (Milano, Italy). Anti–
human phospho-p38, anti–human p38 MAP Kinase, anti–human
phospho-Akt and anti–human Akt antibodies were from Cell Signal-
ing Technology (Milano, Italy). 4-(2-[7-Amino-2-[furyl][1,2,4,]
triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol was obtained
from Tocris Cookson Ltd (Bristol, UK). N -Benzo[1,3]dioxol-5-yl-
2-[5-(2,6-dioxo-1, 3-dipropyl-2,3,6,7-tetrahydro-1H -purin-8-yl)-
1-methyl-1H -pyrazol-3-yloxy]-acetamide (MRE 2029F20) and
5N-(4-methoxyphenyl-carbamoyl)amino-8-propyl-2-(2-furyl)-pyrazolo-
[4,3e]1,2,4-triazolo[1,5c] pyrimidine (MRE 3008F20) were synthesized
by Prof. Pier Giovanni Baraldi (Department of Pharmaceutical Sciences,
University of Ferrara, Italy) [37]. Adenosine A2B and A3 receptors and
HIF-1α small interfering RNA (siRNA) were from Santa Cruz Biotech-
nology, D.B.A. ITALIA s.r.l., Milano, Italy. RNAiFect Transfection Kit
was from Qiagen (Milano, Italy). Unless otherwise noted, all other
chemicals were purchased from Sigma (Milano, Italy).
Cell Culture
A375 humanmelanoma cells weremaintained inDulbecco’smodified
Eagle medium containing 10% fetal calf serum, penicillin (100 U/ml),
streptomycin (100 μg/ml), and L-glutamine (2 mM) at 37°C in 5%
CO2/95% air.
Establishment of Hypoxic Culture Condition
For hypoxic conditions, cells were placed for the indicated times in a
modular incubator chamber and flushed with a gas mixture containing
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1% O2, 5% CO2, and balance N2 (MiniGalaxy; RSBiotech, Irvine,
Scotland). Maintenance of the desired O2 concentration (1%) was
constantly monitored during incubation using a microprocessor-based
oxygen controller. The cells gassed under hypoxic conditions can reach
the 1% oxygen concentration in ∼90 minutes [38].
Cytotoxic Treatment of Cancer Cells
Exponentially growing cells (70%-80% confluence) in complete
medium were treated with different concentrations of cytotoxic drugs,
followed by exposure to hypoxia (1% O2) for different indicated
time intervals.
MTS Assay
The MTS assay was performed to determine cell viability and prolif-
eration according to the manufacturer’s protocol from the CellTiter 96
Aqueous One Solution Cell Proliferation Assay as previously described
[32]. Briefly, 105 cells were plated in 24-multiwell plates; 500 μl of
complete medium was added to each well with different concentrations
of cytotoxic drugs. The cells were then incubated for 24 hours. At the
end of the incubation period,MTS solution was added to each well. The
optical density of each well was read on a spectrophotometer at 570 nm.
For each experiment, four individual wells of each drug concentration
were prepared. Each experiment was repeated three times.
[3H]-Thymidine Incorporation: Cell Proliferation Test
Cells were seeded in fresh medium with 1 μCi/ml of [3H]-thymidine
in Dulbecco’s modified Eagle medium containing 10% fetal calf serum,
penicillin (100 U/ml), streptomycin (100 μg/ml), and L-glutamine
(2 mM). After 24 hours of labeling, cells were trypsinized, dispensed
in four wells of a 96-well plate, and filtered through Whatman GF/C
glass-fiber filters using a Micro-Mate 196 Cell Harvester (Perkin Elmer
Life Sciences,Milano, Italy). The filter-bound radioactivity was counted
on Top Count Microplate Scintillation Counter (efficiency, 57%) with
Micro-Scint 20 (Perkin Elmer Life Sciences).
Flow Cytometry Analysis
A375 adherent cells were trypsinized, mixed with floating cells,
washed with PBS, and permeabilized in 70% (vol/vol) ethanol-PBS
solution at 4°C for at least 24 hours. The cells were washed with PBS,
and the DNA was stained with a PBS solution, containing 20 μg/ml
propidium iodide and 100 μg/ml RNAse, at room temperature for
30 minutes. Cells were analyzed with an EPICS XL flow cytometer
(Beckman Coulter, Miami, FL), and the content of DNAwas evaluated
by the EXPO-32 program (Becton Dickinson Italia Spa, Milano, Italy).
Cell distribution among cell cycle phases and the percentage of apoptotic
cells were evaluated as previously described [30]. Briefly, the cell cycle
distribution is shown as the percentage of cells containing 2n (G0/G1
phases), 4n (G2 andM phases), and 4n > x > 2nDNA amount (S phase)
judged by propidium iodide staining. The apoptotic population is the
percentage of cells with DNA content lower than 2n.
Western Blot Analysis
Whole-cell lysates, prepared as described previously [32], were re-
solved on a 10% SDS gel and transferred onto the nitrocellulose mem-
brane. Western blot analyses were performed as previously described
[31] with anti–HIF-1α (1:250 dilution) and anti–HIF-1β antibodies
(1:1000 dilution) in 5% nonfat dry milk in PBS/0.1% Tween-20 over-
night at 4°C. Aliquots of total protein sample (50 μg) were analyzed
using antibodies specific for phosphorylated (Thr183/Tyr185) or total
p44/p42 MAPK (1:5000 dilution), phosphorylated (Thr180/Tyr182)
or total p38 MAPK (1:1000 dilution), and for phosphorylated or total
Akt (Ser473; 1:1000 dilution). The protein concentration was de-
termined using BCA protein assay kit (Pierce, TEMA ricerca S.r.l.,
Bologna, Italy). Membranes were washed and incubated for 1 hour at
room temperature with peroxidase-conjugated secondary antibodies
againstmouse and rabbit immunoglobulinG (1:2000 dilution). Specific
reactions were revealed with the Enhanced Chemiluminescence West-
ern Blotting Detection Reagent (Amersham, Corp, Arlington Heights,
IL). The membranes were then stripped and reprobed with antitubulin
antibodies (1:250) to ensure equal protein loading.
Densitometry Analysis
The intensity of each band in the immunoblot assay was quantified
using molecular analyst/PC densitometry software (Bio-Rad, Milano,
Italy). Mean densitometry data from independent experiments were
normalized to results in cells in the control. Data were presented as
the mean ± SE.
Treatment of Cells with siRNA
A375 cells were plated in six-well plates and grown to 50% to 70%
confluence before transfection. Transfection of siRNAwas performed at
a concentration of 100 nMusing RNAiFect Transfection Kit. Cells were
cultured in complete medium, and at 48 hours, total proteins were iso-
lated for Western blot analysis of A2B, A3, and HIF-1α protein. A non-
specific random control siRNAwas used under identical conditions [32].
Enzyme-Linked Immunosorbent Assay
The levels of VEGF and IL-8 protein secreted by the cells in the me-
diumwere determined by aVEGFand an IL-8 enzyme-linked immuno-
sorbent assay (ELISA) kit (R&D Systems, DBA,Milano, Italy). In brief,
subconfluent cells were changed into fresh medium in the presence of
solvent or various concentrations of drugs in hypoxia. The medium was
collected, and VEGFand IL-8 protein concentrations weremeasured by
ELISA according to the manufacturer’s instructions. The results were
normalized to the number of cells per plate. Data were presented as mean
± SD from three independent experiments.
Statistical Analysis
All values in the figures and text are expressed as mean ± SE of n
observations (with n ≥ 3). Data sets were examined by Student’s t test
or by the analysis of variance (ANOVA) and Dunnett test (when re-
quired). P < .05 was considered statistically significant.
Results
Cytotoxic Activity of Chemotherapeutic Drugs
All the experiments were performed in hypoxic conditions at 1%O2.
An assessment of growth effects in A375 cells subjected to VP-16 and
doxorubicin for 24 hours was performed by using the MTS assay that
measured viable cell mass. As shown in Figure 1A, A375 melanoma
cells were sensitive to the growth-inhibitory effects of both the DNA-
damaging agents tested. A375 cells were treated with VP-16 and doxo-
rubicin (0.01-100 μM). The cell viability was reduced up to 40 ± 4%
and 30 ± 4% for VP-16 and doxorubicin, respectively (control set at
100%, n = 4). A number of different mechanisms, such as 1) impaired
DNA synthesis, 2) perturbations in cell cycle progression, and 3) induc-
tion of apoptosis, could contribute to the reduction in viable cell mass
seen after treatment with cytotoxic agents. DNA synthesis wasmarkedly
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inhibited in melanoma cells treated with increasing concentrations of
chemotherapeutics (0.01-10 μM). This inhibition was dose-dependent
as determined by tritiated thymidine incorporation after 24 hours of
treatment (Figure 1B). The cytometry investigation showed a clear
arrest in the G2/M and S cell cycle phases of melanoma cells treated with
VP-16, 1 and 10 μM, respectively, to control cells. In particular, low
concentration of VP-16 arrested cells in theG2/Mphase, whereas higher
doses of chemotherapeutic drug were needed to accumulate cell cultures
in the S phase (Figure 1C ). Similar results were obtained when mela-
noma cells were treated for 24 hours with doxorubicin 1 to 10 μM
(Figure 1C ). Furthermore, to evaluate the induction of apoptosis by
chemotherapeutic drugs, A375 cells were incubated with or without
VP-16 anddoxorubicin (1-10μM) for 24hours. As shown inFigure 1D,
both the chemotherapeutic drugs tested were able to significantly in-
duce apoptosis.
Modulation of IL-8 by VP-16 and Doxorubicin
A375 cells were incubatedwithVP-16 and doxorubicin (0.1-10μM),
then IL-8 protein content was measured. As shown in Figure 2A, VP-16
10 μM and doxorubicin 0.1 to 10 μM significantly increased the levels
of IL-8 in A375 cells after 24 hours of treatment.
To determine whether Akt and MAPK pathways were required for
IL-8 increase induced by VP-16 and doxorubicin, A375 cells were pre-
treated for 30 minutes with SH-5, an Akt inhibitor, with SB 202190
and U0126, which are potent inhibitors of p38 MAPK and MEK1/2,
respectively. Cells were then exposed to VP-16 10 μM and doxorubicin
1 μMfor 24 hours. As shown in Figure 2,B andC , SB 202190, U0126,
and SH-5 1 μM were able to completely inhibit VP-16–induced in-
crease of IL-8 protein expression, whereas they inhibited only partially
the effect of doxorubicin.
Furthermore, to evaluate a potential role for adenosine receptors in
the increase of IL-8 induced byVP-16 and doxorubicin, A375 cells were
treated with the chemotherapeutic drugs in combination with 1 μM of
adenosine receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine
(DPCPX; for A1), SCH 58261 (for A2A), MRE 2029F20 (for A2B),
and MRE 3008F20 (for A3). The results indicate that only the A2B
receptor antagonist MRE 2029F20 was able to significantly reduce
IL-8 protein levels in hypoxic A375 cells. Furthermore, as expected,
MRE 2029F20 partially blocked the increase in IL-8 induced by
VP-16 and doxorubicin (Figure 2, B and C ), suggesting that the A2B
receptor induced a signal able to increase IL-8 protein. To confirm this
finding, we stimulated A2B adenosine receptors in A375 cells with in-
creasing concentrations of 5′-N -ethylcarboxamide-adenosine (NECA;
Figure 1. Effect of chemotherapeutic drugs. (A) A375cellswere treatedwith increasing concentrations (0.01-100μM)ofVP-16 ordoxorubicin
(Doxo.) for 24 hours under hypoxic conditions, and cell viability was assayed by anMTS test. MTS: the cell growth is expressed as a percent-
ageof theoptical densitymeasuredonuntreatedcells (control, 100%).Ordinate reportsmeansof fourdifferent optical density quantifications
with SE (vertical bar). During the experiment, cells treatedwith the solventDMSOserved as controls. (B) Antiproliferative activitymeasuredby
[3H]-thymidine incorporation assay. A375 cellswere treatedwith VP-16 or doxorubicin (Doxo.) at the indicated concentrations. [3H]-Thymidine
incorporation is reported aspercentage ofDNA-labeled recovered ondrug vehicle–treated cells. Ordinate reportsmeans of four different [3H]-
thymidine incorporation experiments with standard error (vertical bar). (C) DNA content analysis of A375 cells by flow cytometry. Figures
show percentage cell number of cells in different cell cycle phases. Two representative experiments of A375 cells treated with VP-16, doxo-
rubicin (Doxo.), and DMSO (control) are reported. (D) Apoptosis of A375 cells, by flow cytometry, after treatment with VP-16 or doxorubicin
(Doxo.) at the indicated concentrations (percentage of subdiploid cells). *P< .01 comparedwith the control (untreated cells); analysiswas by
ANOVA followed by Dunnett test.
Neoplasia Vol. 11, No. 10, 2009 A2B/A3 Receptors Interfere with Cytotoxic Drugs Merighi et al. 1067
1-100 μM) for 24 hours. We found that this drug induced the secretion
of IL-8 in a dose-dependent manner (Figure 2D). The relatively low
potency ofNECA agrees with previous reports of A2B receptor–mediated
IL-8 production [28,39].
VP-16 and Doxorubicin Modulate Akt, p44/p42, and p38
MAPK Signaling Pathways
A375 cells were cultured in the absence and in the presence of
VP-16 and doxorubicin for 6 hours. We found that exposure of
melanoma cells to VP-16 10 μM and doxorubicin 1 μM resulted
in the increase of p38, Akt, and ERK1/2 phosphorylation levels (Fig-
ure 3, A and B). Furthermore, we observed that the A2B receptor antag-
onist MRE 2029F20 1 μM was able to attenuate the increase in p38,
Akt, and ERK1/2 phosphorylation levels induced by VP-16 and doxo-
rubicin. In particular, we found that the A2B receptor antagonist MRE
2029F20 1 μM, when used alone, reduces p38, Akt, and ERK1/2
phosphorylation basal levels in A375 cells (Figure 3, A and B).
Modulation of VEGF by VP-16 and Doxorubicin
To investigate VEGF expression, we incubated A375 cells with
VP-16 (5 μM) and doxorubicin (1 μM) and determined VEGF protein
release. As shown in Figure 4A, VP-16 and doxorubicin significantly
decreased the levels of VEGF after 24 hours of treatment.
To determine whether Akt and MAPK pathways were required for
VEGF decrease induced by VP-16 and doxorubicin, A375 cells were
pretreated with 1 μM SH-5, SB 202190, or U0126. Cells were then
exposed to VP-16 5 μMand doxorubicin 1 μM for 24 hours. As shown
in Figure 4, A and B, differently from what we have observed for IL-8-
secretion, SB 202190, U0126, and SH-5were not able to blockVP-16–
and doxorubicin-induced decrease of VEGF protein expression.
To evaluate a potential role for adenosine receptors in the modulation
of VEGF protein levels by VP-16 and doxorubicin, A375 cells were
treated with the chemotherapeutic drugs in combination with 1 μM
DPCPX, SCH58261,MRE2029F20, andMRE3008F20.The results
indicate that the A3 receptor antagonist MRE 3008F20 was able to
Figure 2. Effect of chemotherapeutic drugs on IL-8 expression in hypoxic (1%O2) A375 cells. (A) IL-8 release into the culturemediumofA375
cells cultured for 24 hours in the absence (0) and in the presence of increasing concentrations of VP-16 and doxorubicin. *P< .01 compared
with the control (DMSO-treated hypoxic cells); analysis was by ANOVA followed by Dunnett test. (B and C) IL-8 release into the culture
medium of A375 cells cultured for 24 hours in the absence and in the presence of 1 μM of U0126, SB 202190, SH-5, the A3 antagonist
MRE 3008F20, the A2B antagonist MRE 2029F20, the A2A antagonist SCH 58261, and the A1 antagonist DPCPX 1 μM alone (DMSO) or in
the presence of the chemotherapeutic drug VP-16 5 μM(VP-16; B) or in the presence of the chemotherapeutic drug doxorubicin 1 μM (C); the
inhibitors and the antagonists were added 30 minutes before the chemotherapeutic drug, then the cells were exposed to hypoxia. Ctrl. in-
dicates control and representsDMSO in empty bar andVP-16or doxorubicin alone (filledbar) in panelsB andC, respectively. Plots aremean±
SE values (n=3). *P< .05 comparedwith the control (DMSO-treated hypoxic cells). #P< .05 comparedwith the control (VP-16–treated cells
inpanel B; doxorubicin-treated cells in panel C); analysiswasbyANOVA followedbyDunnett test. (D) Effect of the adenosine receptor agonist
NECA (1, 10, and 100 μM) on IL-8 expression in hypoxic A375 cells after 24 hours of treatment. *P < .01 compared with the control (0;
untreated hypoxic cells). Analysis was by ANOVA followed by Dunnett test.
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further impair VEGF production already decreased byVP-16 and doxo-
rubicin in A375 cells (Figure 4, A and B). Moreover, the A3 receptor
antagonist MRE 3008F20, also when used alone, was able to signifi-
cantly reduce VEGF protein in A375 cells. Furthermore, we studied
the effect of MRE 3008F20 1 μM in combination with different con-
centrations of VP-16 (1, 5, and 10 μM) and doxorubicin (0.1, 0.5, and
1μM)onVEGF production.We found thatMRE3008F20was able to
further reduce VEGF levels already decreased by VP-16 1 to 5 μM and
by doxorubicin 0.5 to 1 μM (Figure 4C ).
VP-16 and Doxorubicin Modulate the Expression of
HIF-1α Protein
The levels of HIF-1α and HIF-1β protein in hypoxic A375 cells on
drug treatment were investigated by Western blot analysis (Figure 5).
HIF-1α protein expression was increased in a time-dependent manner
[31]. In particular, HIF-1α protein expression was detected after
4 hours of exposure to hypoxia, and VP-16 10 μM and doxorubicin
1 μM strongly inhibited HIF-1α protein expression (lanes 2 and 3).
The observed down-regulation of HIF-1α protein expression by the
chemotherapeutic drugs was specific because no alterations were de-
tected in the levels of the HIF-1β protein. Because MRE 3008F20,
when used alone, was able to significantly reduce HIF-1α protein in
A375 cells (Figure 5, lane 4), we have evaluated whether the A3 receptor
antagonist MRE 3008F20 was able to modulate HIF-1α protein when
used in combination with the chemotherapeutic drugs. A375 cells were
treated for 4 hours in hypoxia with VP-16 10 μMor doxorubicin 1 μM
alone and in combination with MRE 3008F20 1 μM. As shown in
Figure 5 (lanes 5 and 6 ), we found that MRE 3008F20 further in-
creased the effect of chemotherapeutic drugs by further decreasing
HIF-1α protein accumulation.
Role of HIF-1α
To investigate a possible role for the HIF-1α subunit in the
chemotherapeutic-induced VEGF inhibition, we have performed a
series of experiments in the presence of siRNAHIF-1α. HIF-1α protein
level was reduced with siRNA at 72 hours after siRNAHIF-1α transfec-
tion (Figure 6, A and B, lane 4 vs lane 1). The results show that when
HIF-1α protein level was reduced by siRNAHIF-1α transfection, VP-16
10 μM and doxorubicin 1 μM further decreased HIF-1α protein con-
tent in A375 cells. Furthermore, siRNAHIF-1α transfection was able to
decrease VEGF protein levels (Figure 6C ). In particular, when HIF-1α
protein level was reduced by siRNAHIF-1α transfection, VP-16 1 μM
and doxorubicin 0.5 μM decreased VEGF secretion levels to a major
extent (Figure 6C ).
A2B and A3 Receptors Gene Silencing
To demonstrate more conclusively a role for A2B or A3 receptors in
the responses being measured, we tried to knock down A2B and A3 re-
ceptors’ expression in hypoxic A375 melanoma cells using siRNA, lead-
ing to a transient knockdown of the A2B and A3 receptor genes. A375
cells were transfected with nonspecific random control ribonucleotides
(siRNA scramble) or with siRNA that target A2B (siRNAA2B) or A3 re-
ceptor messenger RNA (siRNAA3) for degradation. After transfection,
the cells were cultured for 48 hours in complete medium, and then total
proteins were isolated for Western blot analysis of A2B and A3 receptor
protein expressions. As expected, A2B and A3 receptors protein expres-
sions were strongly reduced in siRNAA2B- and siRNAA3-treated cells,
respectively (Figure 7A). To confirm the specificity of the siRNAA3-
mediated silencing of A3 receptor, we investigated the expression of
A2B receptor protein in siRNAA3-treated cells (Figure 7A). Figure 7A
demonstrates that treatment of A375 cells with siRNAA3 reduced the
Figure 3. p38, Akt, and ERK1/2 phosphorylation in hypoxic (1% O2) A375 cells. (A) pp38, phospho-Akt, and pERK1/2 MAPK phospho-
protein levels under VP-16 10 μM and doxorubicin (Doxo) 1 μM treatment in the absence and in the presence of the A2B adenosine
receptor antagonist MRE 2029F20 1 μM. (B) Densitometric data, means from three independent experiments, were normalized to the
results obtained in cells in the absence of drugs (control). Plots are mean ± SE values (n = 3). *P < .01 compared with the control.
Analysis was by ANOVA followed by Dunnett test. #P < .01 compared with cells treated with the chemotherapeutic alone; t test.
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expression of A3 protein but had no effect on the expression of A2B
receptor. Similar results were obtained when A375 cells transfected
with siRNAA2B were analyzed for the expression of the A3 receptor.
Therefore, at 48 hours from the siRNAA2B and siRNAA3 transfection,
A375 cells were exposed to VP-16 10 μM and doxorubicin 1 μM
for 24 hours in hypoxia. Then, IL-8 protein levels were measured.
We found that the inhibition of A2B receptor expression was able to
reduce chemotherapeutic-induced IL-8 accumulation, whereas the
inhibition of A3 receptor expression with siRNAA3 did not modify
chemotherapeutic-induced IL-8 accumulation (Figure 7B). In par-
ticular, the silencing of the A2B receptor by using siRNAA2B alone
was able to significantly reduce basal IL-8 protein secretion in hypoxic
A375 cells (Figure 7B). Furthermore, A375 cells were transfected with
siRNAA2B and siRNAA3 and exposed to VP-16 5 μM and doxorubicin
1 μM for 24 hours in hypoxia to evaluate VEGF levels. No effect in
VEGF inhibition induced by the chemotherapeutic drugs was observed
after the inhibition of A2B receptor expression. On the contrary, the
inhibition of A3 receptor expression potentiates the reduction of VEGF
secretion induced by the chemotherapeutic drugs (Figure 7C). In par-
ticular, the silencing of the A3 receptor by using siRNAA3 alone was able
to significantly reduce VEGF protein in A375 cells (Figure 7C).
Figure 5. (A) Western blot analysis using an anti–HIF-1αmAb of pro-
tein extracts fromA375hypoxic cells (1%O2) under VP-16 10μMand
doxorubicin (Doxo) 1 μM treatment (4 hours) in the absence and
in the presence of the A3 adenosine receptor antagonist MRE
3008F20 1 μM. HIF-1β shows equal protein loading. (B) The mean
densitometric data from three independent experiments were
normalized to the results obtained in cells in the absence of drugs
(control). Plots are mean ± SE values (n = 3). *P < .01 compared
with control without chemotherapeutic treatment; analysis was by
ANOVA followed by Dunnett test. #P< .01 compared with the cells
exposed to chemotherapeutic alone (2 vs 5 and 3 vs 6 for VP-16
and doxorubicin, respectively). Analysis was by t test.
Figure 4. Effect of chemotherapeutic drugs on VEGF expression in
hypoxic (1%O2) A375 cells. (A) VEGF release into the culturemedium
ofA375cells cultured for 48 hours in the absence and in thepresence
(1 μM) of U0126, SB 202190, SH-5, the A3 antagonist MRE 3008F20,
theA2B antagonistMRE 2029F20, theA2A antagonist SCH58261 and
the A1 antagonist DPCPX alone (DMSO) or in the presence of the
chemotherapeutic drug VP-16 5 μM (VP-16; A) or in the presence
of the chemotherapeutic drug doxorubicin 1 μM (B); the inhibitors
and the antagonists were added 30minutes before the chemothera-
peutic drug, then thecellswereexposed tohypoxia. Plots aremean±
SE values (n = 3). *P < .05 MRE 3008F20 plus chemotherapeutic
drug–treated cells versus chemotherapeutic drug–treated cells: black
filled bar indicates Ctrl.; analysis was by t test. #P < .05 compared
with the control (DMSO-treated cells: empty bar indicates Ctrl.); anal-
ysis was by ANOVA followed by Dunnett test. (C) VEGF release into
the culture medium of A375 cells cultured for 48 hours in the pres-
ence of increasing concentrations of the chemotherapeutic drug
VP-16 (1-5-10 μM) and doxorubicin (0.1-0.5-1 μM) in the absence
and in the presence of the A3 antagonist MRE 3008F20 1 μM, which
was added 30 minutes before the chemotherapeutic drug. Then the
cells were exposed to hypoxia. *P< .05: MRE 3008F20-treated cells
versusDMSO-treated cells; analysiswasby t test. #P< .05compared
with the control (DMSO-treated hypoxic cells: empty bar indicates
Ctrl.); analysis was by ANOVA followed by Dunnett test.
1070 A2B/A3 Receptors Interfere with Cytotoxic Drugs Merighi et al. Neoplasia Vol. 11, No. 10, 2009
Discussion
New treatments are urgently needed for the therapy for metastatic
melanoma, and much effort is being devoted to the development of
genetic and immune therapies, but the widespread availability of these
remains a distant prospect. In the meantime, chemotherapy will remain
the treatment of choice, and strategies to overcome resistance offer a
more immediate possibility for improving the lot of these patients.
This study was undertaken to examine whether two chemotherapeutic
drugs, VP-16 and doxorubicin, modulate IL-8 and VEGF production
in human melanoma A375 cells. In particular, because adenosine was
able to modulate HIF-1, VEGF, and IL-8 in cancer cells, we analyzed
the influence of the adenosinergic signaling on the chemotherapeutic
drug effects in human melanoma cells.
The aims of this study were as follows:
1. to investigate the effect of two drugs used in chemotherapy on
cell vitality and on cytokine release induced in melanoma cells
under hypoxic conditions;
2. to define a molecular signaling of the cancer cell response to
these drugs; and
3. to investigate the putative role of the adenosinergic system in
these processes.
We demonstrated that human melanoma cells produce IL-8 and
VEGF. In particular, we found that treatment of melanoma cells with
the DNA-damaging drugs VP-16 and doxorubicin resulted in the up-
regulation of the proangiogenic cytokine IL-8 (Figure 2). These results
are in accord with data indicating that in addition to their known cyto-
toxic effects, chemotherapeutic agents can trigger cytokine production
in a variety of cell types in vitro [40,41].Moreover, our data indicate that
the DNA-damaging drugs VP-16 and doxorubicin inhibit VEGF ex-
pression (Figure 4) through the inhibition of HIF-1 (Figure 5).
A further objective of these studies was to assess whether the adeno-
sinergic signaling, through its adenosine receptor subtypes, couldmodu-
late cytokine production induced by chemotherapeutic agents. Using
the human A375 melanoma cell line that expresses each of the four
adenosine receptor subtypes [25], these studies demonstrated that the
A2B receptor blockade can modulate IL-8 production, whereas blocking
A3 receptors, it is possible to further decrease VEGF reduction because
of VP-16 and doxorubicin. In this work, we have demonstrated that the
inhibition of the A2B receptor results in the reduction of IL-8 produc-
tion, whereas inhibition of A3 results in the reduction of VEGF. Ac-
cording to these results, it has been previously demonstrated that
stimulation of A2B adenosine receptors increased synthesis and secretion
of IL-8, whereas A3 receptors are responsible of the increase of VEGF
[27,28]. We hypothesize that the different effects of A2B and A3 adeno-
sine receptors on the synthesis of angiogenic factors may imply their
coupling to different G proteins.
The mechanism of how A2B adenosine receptor could decrease
chemotherapy-induced cytokine production was also examined and
was found to be dependent on the activation of MAPK. The current
findings describe a putative mechanism by which this G protein–
coupled receptor can decrease the cytokine-producing effects of chemo-
therapeutic agents in human melanoma.
Hypoxic cancer cells are resistant to chemotherapeutic treatment,
leading to the selection of cells with a more malignant phenotype.
HIF-1 has been shown to be responsible for an adaptive response of cells
to hypoxia. If VP-16 would influence its activity under hypoxia, this
could lead to changes in cell survival. To investigate this possibility,
we measured HIF-1α protein level. The results indicate that hypoxia
did increase HIF-1α protein level in melanoma cells, and this effect
was influenced by VP-16 (Figure 5).
Dacarbazine remains the reference standard treatment of metastatic
melanoma, but only a minority of patients obtains long-lasting re-
sponses [7]. Polychemotherapy regimens have been reported to produce
various response rates. Treatment with VP-16 is more common in lung
Figure 6. (A) Western blot analysis using an anti–HIF-1αmAb of pro-
tein extracts from A375 cells transfected with scramble ribonucleo-
tides (siRNActr.) or siRNAHIF-1α for 72 hours and cultured with VP-16
10 μMand doxorubicin (Doxo) 1 μM for 4 hours. HIF-1β shows equal
protein loading. (B) The means of densitometry data from inde-
pendent experimentswerenormalized to the results obtained in cells
transfected with siRNActr. Plots are mean ± SE values (n= 3). *P<
.01 compared with the siRNActr. without chemotherapeutic drug
treatment. Analysis was by ANOVA followed by Dunnett test. #P <
.01 cells treated with siRNAHIF-1α compared with cells treated with
siRNActr (2 vs 5 for VP-16; 3 vs 6 for doxorubicin). Analysis was by
t test. (C) VEGF release into the culture medium of A375 cells trans-
fected with scramble siRNA or with siRNAHIF-1α for 48 hours and
then cultured for 24 hours in hypoxia in the absence (Control) and
in the presence of VP-16 1 μM and doxorubicin (Doxo) 0.5 μM. Plots
are mean ± SE values (n = 3). *P < .01 compared with the Control-
siRNA-scramble–transfected cells (black filled bar); analysis was by
ANOVA followed by Dunnett test. #P< .01 siRNAHIF-1α versus siRNA
scramble; analysis by t test.
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cancer, leukemia, and testicular tumors and has been used in poly-
chemotherapy regimens combined with cisplatin for the treatment
of melanoma brain metastases, but the response rates remain less than
13% [42].
The significance of tumor cell–derived cytokine production in the
therapeutic effectiveness or adverse effect profile of chemotherapeutic
agents is unclear. However, significant levels of cytokines, including
IL-8, tumor necrosis factor α, and others, can be found in patients
undergoing chemotherapy for a variety of tumors [43,44]. It has been
reported that overproduction of chemokines is a potential mechanism
for melanoma cells to evade cell death and become resistant to chemo-
therapy. Strategies to inhibit IL-8 signaling may sensitize hypoxic tumor
cells to conventional treatments.
These data may have a significant clinical relevance, justifying the
combination of conventional chemotherapy with anti–IL-8 and/or
anti-VEGF modalities, such as A2B or A3 adenosine receptor antago-
nists, for the treatment of malignant melanoma.
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